Parabilis breaks IPO record with $670M raise

Good morning, healthcare professional.

Biotech markets are showing renewed vigor as Parabilis secures the largest IPO in sector history, while major pharmaceutical players deliver pivotal clinical trial results that could reshape competitive dynamics in psoriasis and rare disease treatment. Meanwhile, federal investigators are exposing systematic barriers to care in private Medicare plans.

These developments signal both opportunity and accountability across the healthcare landscape. Record capital raises suggest investor confidence is returning after years of drought, successful head-to-head trials are validating billion-dollar bets, and regulatory scrutiny is intensifying around patient access issues.

In today's healthcare digest:

• Parabilis achieves record-breaking $670 million biotech IPO
• Takeda's TYK2 inhibitor outperforms competitor in Phase 3 psoriasis trial
• Novartis validates $12 billion Avidity acquisition with positive RNA therapy data
• Federal investigation reveals Medicare Advantage plans systematically deny legitimate rehab claims

Parabilis Sets Biotech IPO Record at $670 Million

Parabilis has completed the largest biotech IPO on record with a $670 million offering, marking a significant turning point for public market confidence in the sector. The Helicon-backed company focuses on peptide-based cancer therapies developed by chemistry pioneer Verdine.

Unpacked:

• The offering represents the biggest biotech public debut ever recorded, surpassing previous benchmarks during more favorable market conditions.
• Parabilis specializes in peptide therapeutics for oncology, a modality gaining traction as companies seek alternatives to traditional small molecules and biologics.
• The successful raise signals renewed investor appetite for biotech IPOs after years of challenging capital markets and widespread sector pullback.

Takeda's Psoriasis Drug Beats Bristol Myers in Head-to-Head Trial

Takeda's TYK2 inhibitor has demonstrated superiority over Bristol Myers Squibb's Sotyktu in a Phase 3 head-to-head trial for psoriasis treatment. The positive results represent a major validation for Takeda's $4 billion drug candidate.

Unpacked:

• The trial directly compared Takeda's zasocitinib against Sotyktu, providing rare head-to-head efficacy data that payers and physicians heavily value.
• TYK2 inhibitors represent a newer mechanism of action in psoriasis treatment, offering an alternative to established JAK inhibitors and biologics.
• The win positions Takeda to capture significant market share in the competitive psoriasis space, where multiple blockbuster drugs already compete.

Novartis RNA Therapy Validates $12 Billion Avidity Bet

Novartis reported successful trial data for del-brax, an RNA-targeted therapy acquired through its $12 billion purchase of Avidity Therapeutics. The positive results provide early validation for the massive acquisition investment.

Unpacked:

• Del-brax uses antibody-oligonucleotide conjugate technology to deliver RNA-targeted treatments, representing a novel approach to drug delivery and mechanism.
• The trial success helps justify Novartis's record-breaking bet on RNA therapeutics, one of the largest biotech acquisitions in recent years.
• Positive data reduces integration risk and supports Novartis's broader strategy to build leadership in RNA-based drug development.

Medicare Advantage Plans Systematically Block Rehab Access, Feds Find

A federal Office of Inspector General investigation has revealed that private Medicare Advantage plans systematically create barriers to rehabilitation care in pursuit of profit. The report shows plans frequently deny legitimate claims only to reverse decisions on appeal.

Unpacked:

• Investigators identified suspicious denial patterns where plans reject medically necessary rehab care, then reverse upon appeal after delaying treatment.
• The practice creates unnecessary obstacles for patients seeking legitimate care while potentially generating cost savings through administrative friction.
• Federal scrutiny could trigger regulatory action or policy changes affecting how Medicare Advantage plans manage prior authorization and appeals.

The Shortlist

• Summit Therapeutics pulled a $500 million share sale just one day after announcing the offering, citing market conditions.

• Novo Nordisk reported a data breach affecting clinical trial participants and advised patients to remain vigilant for potential identity theft.

• Genentech executed another round of layoffs with three vice presidents among those terminated as restructuring continues.

• Johnson & Johnson reported positive trial results that could expand Imaavy into rare disease indications beyond its current approved uses.

• Sanofi stopped an immune drug trial for rilipubart in CIDP, marking another research setback for the company's pipeline.